Subscribe
istock-508496956cosmin4000
cosmin4000 / iStockphoto.com
8 May 2018AfricaTimo Minssen, Esther van Zimmeren, Jakob Wested

Clearing a way through the CRISPR patent jungle

The revocation of the Broad Institute’s patent EP2771468, reported and discussed here, marks the latest major development in a series of patent battles over the revolutionary and highly lucrative CRISPR/Cas 9 technology (and other gene-editing technologies) in the US and Europe.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Will the EPO’s Enlarged Board hear the Broad’s CRISPR case?
13 July 2018   As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.
Europe
CRISPR in Europe: the patent landscape for 2018
30 November 2017   The Broad Institute of MIT and Harvard may lose a substantial number of European patent claims covering CRISPR/Cas9, but it has at least one trump card to play before we get to that stage, one European patent attorney has told LSIPR.
Americas
Broad Institute takes three lines of attack in CRISPR appeal filing
26 October 2017   The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Killing the golden goose of US drug innovation (Part I): Follow the money
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Smart ringleader: Could Ōura’s market dominance be under threat?
Roche resolves cancer test dispute with Stanford affiliated startup
UK firm expands in Germany with more litigation hires